

Diagnostic update

Catalyst proBNP Test: practical application and clinical decision-making in dogs and cats

The measurement of NT-proBNP has been demonstrated to be a highly informative biomarker that can help clinicians to assess cardiac health in both dogs and cats. The Catalyst™ proBNP Test combines the in-clinic convenience of the SNAP™ Feline proBNP Test with the precise quantification offered by the IDEXX Reference Laboratories Cardiopet™ proBNP Test, thereby allowing clinicians to obtain an accurate and precise point-of-care measurement of NT-proBNP.

What is NT-proBNP?

B-type natriuretic peptide (BNP) is stored in cardiomyocytes as a prohormone (proBNP) and is released in response to stretch or strain on heart muscle.¹ On release, proBNP is cleaved into a biologically active hormone C-BNP and an inactive amino-terminal fragment (NT-proBNP). The C-BNP hormone acts on blood vessels to induce vasodilation as well as promoting natriuresis and diuresis in the kidney. NT-proBNP has a longer half-life than C-BNP, making the quantification of circulating NT-proBNP more amenable for clinical purposes. NT-proBNP is released in proportion to the amount of stretch and stress on the myocardium, with concentrations tending to increase with severity of cardiac disease.

Heart disease in dogs and cats

Approximately 10% of dogs are estimated to have heart disease with myxomatous mitral valve disease (MMVD) being the most common canine cardiac disorder diagnosed.² The disease typically affects small- to medium-sized dog breeds, such as Cavalier King Charles spaniel (CKCS), Maltese, Chihuahua, Yorkshire terrier, miniature schnauzer, and dachshunds. Dilated cardiomyopathy (DCM)

is the other major acquired cardiac disease in dogs, which typically affects larger breeds, such as Doberman pincher, Irish wolfhound, boxer and Weimaraner. In cats, hypertrophic cardiomyopathy (HCM) is the most common cause of heart disease with an estimated prevalence of 15% in the general cat population.³

Diagnosing heart disease in dogs and cats

Dogs and cats with early-stage heart disease will typically present to vets without any clinical signs, and the only abnormality detected on physical examination may be the presence of a murmur or arrhythmia on cardiac auscultation. The presence of a gallop sound may also be detected in cats. In patients where a murmur is heard on auscultation, it is important to establish whether the murmur is caused by an underlying cardiac disorder or is an innocent murmur. A smaller proportion of cases with cardiac disease will present with clinical signs of heart failure, which may include respiratory distress in dogs and cats or coughing in dogs.

The most definitive way to diagnose structural heart disease in dogs and cats is with an echocardiography performed by a veterinary cardiology specialist.^{2,3} However, access to a veterinary cardiologist may not be feasible for all patients. Therefore, measurement of NT-proBNP can be a highly informative, cost-effective alternative, especially in the context of screening cats for subclinical disease as well as providing insights as to whether dogs and cats with respiratory distress have an underlying cardiac or respiratory disorder. Measurement of NT-proBNP is also helpful in the assessment of small-medium breed, healthy dogs which have a murmur.


How can the Catalyst™ proBNP Test help?

Measurement of NT-proBNP in the point-of-care setting can be helpful in three key clinical scenarios:

Does the cat have subclinical (occult) cardiac disease?

Approximately 1 in 6 cats have heart disease, but not all cases will present with a heart murmur.^{4,5} On the other hand, 1 out of 4 apparently healthy cats may have a murmur, but less than half of these cats will have evidence of cardiomyopathy by echocardiogram.⁴⁻⁷ Consequently, it is difficult to accurately assess whether

a cat has subclinical heart disease based on clinical examination alone. The presence of an accurate and precise point-of-care test that quantifies NT-proBNP may provide supportive information to assist in the timely and efficient assessment of cardiac disease risk in senior cats as part of their routine, annual health check or as part of a preanaesthetic health evaluation.⁸ Healthy cats with an NT-proBNP > 100 pmol/L are at increased risk of having a subclinical cardiomyopathy, and further cardiac evaluation with an echocardiogram is recommended, especially if they are male, overweight, or have a murmur grade ≥ 3/6 (figure 1).^{9,10}



*Asymptomatic cats that may be at an increased risk of cardiac disease include cats with a murmur, arrhythmia, or gallop sound detected on cardiac auscultation.


†Echocardiography is the gold-standard technique for the assessment of cardiac structure and function. Cats with an increased left atrial size +/- left ventricular hypertrophy detected by point-of-care cardiac ultrasound and a NT-proBNP result > 100 pmol/L are likely to have cardiac disease. Consider patient and client factors as part of a spectrum-of-care approach to diagnostic selection.

Figure 1. Diagnostic algorithm describing the use of NT-proBNP to assess asymptomatic cats for the presence of subclinical heart disease.

Does the healthy small- to medium-breed dog with a murmur and suspected MMVD have stage B1 or B2 disease?

Dogs with MMVD will often present without clinical signs, and the only abnormality detected on clinical examination is a systolic murmur. On echocardiogram, dogs with a heart murmur but no signs of cardiac remodelling are classified to have stage B1 heart disease. Many dogs will ultimately develop echocardiographic evidence of left atrial and ventricular enlargement, which is defined as stage B2 heart disease. At this point, medical intervention is recommended to delay the onset of cardiac failure.² At initial presentation, it is not possible to establish whether the dog is in stage B1 or B2 by physical examination alone, and echocardiography

is required to definitively stage the heart disease. Thoracic radiographs are recommended when echocardiography is unavailable. However, not all patients have access to echocardiography or radiography, and in this scenario, the measurement of NT-proBNP can be used to assess the likelihood of stage B2 disease. When imaging is available, NT-proBNP can be a helpful additional tool to inform the assessment of equivocal cases and as a baseline for future trending. Published studies suggest that healthy small- to medium-breed dogs with a murmur consistent with MMVD are unlikely to have stage B2 disease if their NT-proBNP concentration is below 500 pmol/L. In contrast, dogs with an NT-proBNP concentration above 1,200 pmol/L are likely to have stage B2 disease (figure 2).^{11,12}



*Echocardiography is the gold-standard technique for the assessment of cardiac structure and function. Thoracic radiographs and measurements taken from them, including vertebral heart score (VHS) and vertebral left atrial size (VLAS), may provide information on heart size. Consider patient and client factors as part of a spectrum-of-care approach to diagnostic selection.


†Further assessment may include echocardiography, thoracic radiography, blood pressure assessment, CBC, biochemistry, electrocardiogram, infectious disease testing, urinalysis, and abdominal ultrasonography.

Figure 2. Diagnostic algorithm describing the use of NT-proBNP to assess the likelihood of stage B2 disease in healthy small- to medium-breed dogs with a heart murmur consistent with MMVD.

Is cardiac disease the cause of the dog's or cat's breathing difficulties?

Dogs and cats in respiratory distress often present as an acute clinical emergency. The underlying cause of the clinical signs can be difficult to establish based purely on physical examination. The point-of-care measurement of NT-proBNP may provide valuable supportive information to help differentiate whether the respiratory distress is caused


by primary cardiac or respiratory disease. A concentration of > 270 pmol/L in cats (figure 3)¹³ and > 2,500 pmol/L in dogs (figure 4)¹⁴ with breathing difficulties is strongly suggestive that cardiac disease, rather than respiratory disease, is the cause of the clinical signs. The upper cutoff for NT-proBNP has changed from 1,800 to 2,500 pmol/L following a detailed review of Cardiopet™ proBNP Test data, NT-proBNP publications, and input from cardiology specialists.



*Echocardiography is the gold-standard technique for the assessment of cardiac structure and function. Cats with an increased left atrial size +/- ventricular hypertrophy detected by point-of-care cardiac ultrasound and a NT-proBNP result > 100 pmol/L are likely to have cardiac disease. Thoracic radiographs recommended for stabilized patients with dyspnea and tachypnea. Consider patient and client factors as part of a spectrum-of-care approach to diagnostic selection.

†Further assessment may include T₄, blood pressure assessment, echocardiography, thoracic radiography, CBC, biochemistry, electrocardiogram, and urinalysis.

Figure 3. Diagnostic algorithm describing the use of NT-proBNP to assess the likelihood of heart failure in cats with respiratory clinical signs.



*Echocardiography is the gold-standard technique for the assessment of cardiac structure and function. Thoracic radiographs recommended for stabilized patients with dyspnea, tachypnea, and coughing. Consider patient and client factors as part of a spectrum-of-care approach to diagnostic selection.

†Further assessment may include thoracic radiography, echocardiography, blood pressure assessment, CBC, biochemistry, infectious disease testing, urinalysis, abdominal ultrasonography, and electrocardiogram.

Figure 4. Diagnostic algorithm describing the use of NT-proBNP to assess the likelihood of heart failure in dogs with respiratory clinical signs.

Can the Catalyst™ proBNP Test help with other clinical cases?

There are numerous other clinical scenarios in which measurement of NT-proBNP can help support clinical decision-making and patient care, including the following:

NT-proBNP can be used to screen for dilated cardiomyopathy in some at-risk dog breeds

Doberman pinschers and Weimaraners with an NT-proBNP concentration above 500 pmol/L¹⁵ and 405 pmol/L,¹⁶ respectively, are at increased risk of heart disease, and further evaluation with an echocardiogram and Holter

monitor is advised. These thresholds are breed-specific and not generalizable to all dogs.

Assessment of ascites in dogs

NT-proBNP can be used to help distinguish cardiac and noncardiac causes of nonhemorrhagic ascites. A study found that median NT-proBNP concentration in dogs with nonhemorrhagic ascites caused by cardiac disease (4,510 pmol/L) was higher than in dogs where the ascites was caused by noncardiac causes (739 pmol/L).¹⁷ The two groups could be distinguished with a sensitivity of 54% and specificity of 86% when using a NT-proBNP concentration cutoff of 4,092 pmol/L.

Assessing response to therapy and predicting long-term outcomes in dogs

In a study of 30 dogs with stage B2 MMVD, mean plasma NT-proBNP concentrations significantly decreased from 1,615 pmol/L to 959 pmol/L following 7–10 days of pimobendan treatment.¹⁸ A study of 168 dogs with preclinical MMVD found that a NT-proBNP concentration > 1,500 pmol/L was associated with increased risk of heart failure or cardiac death.¹⁹

Predicting severity of cardiac disease in cats

Median plasma NT-proBNP concentrations in mildly (216 pmol/L), moderately (283 pmol/L), and severely (840 pmol/L) affected HCM cats were significantly higher than healthy controls (19 pmol/L).²⁰

Assessing response to therapy and predicting long-term outcome in cats

In a study of 31 cats with CHF, median serum NT-proBNP concentrations decreased significantly from admission (1,713 pmol/L) to discharge (902 pmol/L) and from admission to re-evaluation in 7–10 days time (1,124 pmol/L).²¹ In a study of 25 cats with a cardiomyopathy and CHF, median serum concentrations of baseline NT-proBNP was significantly higher in the cats that died (> 1,500 pmol/L, n = 13) than in those that were alive (780 pmol/L, n = 12) at follow-up.²²

Are there any other factors that I need to consider when interpreting Catalyst proBNP Test results?

Renal function

NT-proBNP is cleared primarily by the kidney, and thus, significant renal insufficiency or pre- or postrenal azotemia may lead to increased concentrations. Therefore, NT-proBNP concentrations should always be interpreted alongside biomarkers of renal function, such as SDMA, creatinine, and urine specific gravity.^{23,24}

Hyperthyroidism

Hyperthyroidism can cause secondary cardiac pathology in cats, leading to increased NT-proBNP concentrations.^{25,26} However, increased NT-proBNP concentrations in cats with hyperthyroidism should not be automatically assumed to be caused by elevated thyroxine concentrations

since hyperthyroidism and a cardiomyopathy can occur as distinct, independent disease processes. Cats with hyperthyroidism and an increased NT-proBNP concentration should have their NT-proBNP concentration monitored following hyperthyroid treatment. Cats with persistently increased NT-proBNP concentrations following a return to a euthyroid state should undergo further cardiac evaluation.

Breed

Breed-related differences in NT-proBNP concentrations have been reported.^{27,28} The interpretative guidelines are for a general canine population since breed specific reference intervals have only been described for a small number of dog breeds. The breeds for which reference intervals have been reported include Chihuahua (125–2121 pmol/L),²⁹ Labrador retriever (275–2,100 pmol/L),³⁰ and Saluki (250–769 pmol/L).³¹ Unlike dogs, breed has not been found to influence NT-proBNP concentrations in cats.³²

Individual variation

NT-proBNP concentrations can vary significantly in healthy dogs^{30,33,34} and in dogs with cardiac disease.^{34,35} Similarly, NT-proBNP concentrations can vary significantly in healthy cats.³⁶ When the patient has no or very early cardiac pathology, assessment of NT-proBNP concentrations can be helpful in determining whether changes in NT-proBNP concentrations are clinically relevant for that patient. Dogs and cats with an increase of 60% in NT-proBNP concentration should undergo a more detailed re-evaluation of their cardiac health.

Summary

The Catalyst™ proBNP Test is an immunologic assay that is specifically designed to align with the Cardiopet™ proBNP Test to provide quantitative NT-proBNP results at the point-of-care for dogs and cats. The Catalyst proBNP Test has a wide dynamic range and provides results in approximately 16 minutes in lithium heparin plasma and serum samples. Having accurate and reliable measurement of NT-proBNP during the patient visit enables timely, in-person communication with pet owners. This not only supports shared decision-making, but it may also enhance client understanding and adherence to subsequent diagnostic and treatment recommendations.

References

- Bode L, Lau S. Interpreting cardiac biomarkers in small animal practice. *In Pract.* 2023;45(7):372–382. doi:10.1002/inpr.349
- Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. *J Vet Intern Med.* 2019;33(3):1127–1140. doi:10.1111/jvim.15488
- Luis Fuentes V, Abbott J, Chetboul V, et al. ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. *J Vet Intern Med.* 2020;34(3):1062–1077. doi:10.1111/jvim.15745
- Paige CF, Abbott JA, Elvinger F, Pyle RL. Prevalence of cardiomyopathy in apparently healthy cats. *JAVMA.* 2009;234(11):1398–1403. doi:10.2460/javma.234.11.1398
- Payne JR, Brodbelt DC, Luis Fuentes V. Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). *J Vet Cardiol.* 2015;17 Suppl 1:S244–S257. doi:10.1016/j.jvc.2015.03.008
- Nakamura RK, Rishniw M, King MK, Sammarco CD. Prevalence of echocardiographic evidence of cardiac disease in apparently healthy cats with murmurs. *J Feline Med Surg.* 2011;13(4):266–271. doi:10.1016/j.jfms.2010.12.007
- Côté E, Manning AM, Emerson D, Laste NJ, Malakoff RL, Harpster NK. Assessment of the prevalence of heart murmurs in overtly healthy cats. *JAVMA.* 2004;225(3):384–388. doi:10.2460/javma.2004.225.384
- Dhaliwal R, Boynton E, Carrera-Justiz S, et al. 2023 AAHA Senior Care Guidelines for Dogs and Cats. *J Am Anim Hosp Assoc.* 2023;59(1):1–21. doi:10.5326/JAAHA-MS-7343
- Carter R, Partington C, Novo Matos J. Accuracy of combined signalment, physical examination and cardiac biomarkers in screening cats with asymptomatic murmurs for cardiac disease. *J Vet Intern Med.* 2026;40(1):aala037. doi:10.1093/jvims/aala037
- Lu TL, Côté E, Kuo YW, Wu HH, Wang WY, Hung YW. Point-of-care N-terminal pro B-type natriuretic peptide assay to screen apparently healthy cats for cardiac disease in general practice. *J Vet Intern Med.* 2021;35(4):1663–1672. doi:10.1111/jvim.16156
- Wesselowski S, Gordon SG, Fries R, et al. Use of physical examination, electrocardiography, radiography, and biomarkers to predict echocardiographic stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels. *J Vet Cardiol.* 2023;50:1–16. doi:10.1016/j.jvc.2023.10.001
- Wilshaw J, Rosenthal SL, Wess G, et al. Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease. *J Vet Intern Med.* 2021;35(2):755–770. doi:10.1111/jvim.16083
- Fox PR, Oyama MA, Reynolds C, et al. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats. *J Vet Cardiol.* 2009;11 Suppl 1:S51–S61. doi:10.1016/j.jvc.2008.12.001
- Fox PR, Oyama MA, Hezzell MJ, et al. Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay. *J Vet Intern Med.* 2015;29(1):171–179. doi:10.1111/jvim.12472
- Wess G, Domenech O, Dukes-McEwan J, Häggström J, Gordon S. European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers. *J Vet Cardiol.* 2017;19(5):405–415. doi:10.1016/j.jvc.2017.08.006
- Filipejová Z, Metelková L, Kosková B, et al. The occurrence of preclinical dilated cardiomyopathy in the Weimaraner dog breed and the prognostic importance of cardiac markers. *Acta Vet Brno.* 2024;93:397–404. doi:10.2754/avb202493040397
- Morey AGN, Lamb KE, Karnia JJ, et al. N-terminal brain natriuretic peptide, cardiac troponin-I, and point-of-care ultrasound in dogs with cardiac and noncardiac causes of nonhemorrhagic ascites. *J Vet Intern Med.* 2023;37(3):900–909. doi:10.1111/jvim.16702
- Kaplan JL, Visser LC, Gunther-Harrington CT, et al. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease. *J Vet Intern Med.* 2022;36(6):1892–1899. doi:10.1111/jvim.16537
- Borgarelli M, Ferasin L, Lamb K, et al. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study. *J Vet Cardiol.* 2021;36:77–88. doi:10.1016/j.jvc.2021.04.009
- Wess G, Daisenberger P, Mahling M, Hirschberger J, Hartmann K. Utility of measuring plasma N-terminal pro-brain natriuretic peptide in detecting hypertrophic cardiomyopathy and differentiating grades of severity in cats. *Vet Clin Pathol.* 2011;40(2):237–244. doi:10.1111/j.1939-165X.2011.00305.x
- Pierce KV, Rush JE, Freeman LM, Cunningham SM, Yang VK. Association between survival time and changes in NT-proBNP in cats treated for congestive heart failure. *J Vet Intern Med.* 2017;31(3):678–684. doi:10.1111/jvim.14690
- Liu M, Köster LS, Fosgate GT, et al. Cardiovascular-renal axis disorder and acute-phase proteins in cats with congestive heart failure caused by primary cardiomyopathy. *J Vet Intern Med.* 2020;34(3):1078–1090. doi:10.1111/jvim.15757
- Lalor SM, Connolly DJ, Elliott J, Syme HM. Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disease. *J Vet Cardiol.* 2009;11 Suppl 1:S71–S79. doi:10.1016/j.jvc.2009.01.004
- Hezzell MJ, Foster JD, Oyama MA, et al. Measurements of echocardiographic indices and biomarkers of kidney injury in dogs with chronic kidney disease. *Vet J.* 2020;255:105420. doi:10.1016/j.tvjl.2019.105420
- Menaut P, Connolly DJ, Volk A, et al. Circulating natriuretic peptide concentrations in hyperthyroid cats. *J Small Anim Pract.* 2012;53(12):673–678. doi:10.1111/j.1748-5827.2012.01301.x
- Sangster JK, Panciera DL, Abbott JA, Zimmerman KC, Lantis AC. Cardiac biomarkers in hyperthyroid cats. *J Vet Intern Med.* 2014;28(2):465–472. doi:10.1111/jvim.12259
- Couto KM, Iazbik MC, Marin LM, et al. Plasma N-terminal pro-B-type natriuretic peptide concentration in healthy retired racing Greyhounds. *Vet Clin Pathol.* 2015;44(3):405–409. doi:10.1111/vcp.12266
- Sjöstrand K, Wess G, Ljungvall I, et al. Breed differences in natriuretic peptides in healthy dogs. *J Vet Intern Med.* 2014;28(2):451–457. doi:10.1111/jvim.12310
- Galizzi A, Dossi G, Pocar P, Borromeo V, Locatelli C. Plasma N-terminal pro-B-type natriuretic peptide and urinary aldosterone-to-creatinine ratio in healthy Chihuahuas. *BMC Vet Res.* 2024;20(1):501. doi:10.1186/s12917-024-04344-w
- Gomart S, Allaway D, Harrison M, et al. Long-term biological variability and the generation of a new reference interval for plasma N-terminal pro-B-type natriuretic peptide in Labrador retrievers. *J Small Anim Pract.* 2020;61(6):368–373. doi:10.1111/jsap.13136
- Brennan C, Gunasekaran T, Sanders RA. Evaluation of plasma N-terminal pro-B-type natriuretic peptide levels in healthy North American Salukis with normal echocardiographic measurements. *PLoS One.* 2022;17(1):e0260079. doi:10.1371/journal.pone.0260079
- Hanås S, Holst BS, Höglund K, Häggström J, Tidholm A, Ljungvall I. Effect of feline characteristics on plasma N-terminal-prohormone B-type natriuretic peptide concentration and comparison of a point-of-care test and an ELISA test. *J Vet Intern Med.* 2020;34(3):1187–1197. doi:10.1111/jvim.15754
- Kelliham HB, Oyama MA, Reynolds CA, Stepien RL. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. *J Vet Cardiol.* 2009;11 Suppl 1:S93–S97. doi:10.1016/j.jvc.2009.03.003
- Ruau X, Scollan K, Suchodolski JS, Steiner JM, Sisson DD. Biologic variability in NT-proBNP and cardiac troponin-I in healthy dogs and dogs with mitral valve degeneration. *Vet Clin Pathol.* 2015;44(3):420–430. doi:10.1111/vcp.12268
- Winter RL, Saunders AB, Gordon SG, Buch JS, Miller MW. Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease. *J Vet Cardiol.* 2017;19(2):124–131. doi:10.1016/j.jvc.2016.11.001
- Harris AN, Estrada AH, Gallagher AE, et al. Biologic variability of N-terminal pro-brain natriuretic peptide in adult healthy cats. *J Feline Med Surg.* 2017;19(2):216–223. doi:10.1177/1098612X15623825

Published August 2026.

The information contained herein is intended to provide general guidance only. As with any diagnosis or treatment, you should use clinical discretion with each patient based on a complete evaluation of the patient, including history, physical presentation, and complete laboratory data. With respect to any drug therapy or monitoring program, you should refer to product inserts for a complete description of dosages, indications, interactions, and cautions.